Oriental Aromatics Ltd Q3 FY2026 Concall Summary

Source transcript PDF: https://www.stockscans.in/document/ivygdzasb7pvf6zw0sc794qy.pdf

Key Takeaways


Volume Strategy vs Pricing Reality

Management: "Between 2018 and 2026, we see a completely different oriental where we have a large range of materials. These materials are used by our fragrance division. We have internalized our formulated camphor. So, a lot of things are now ready for action when the opportunities come."

Mahad Greenfield: The Ramp-Up Equation

Management: "we already have reached around, I mean, to be very honest, the real production in that plant has only started from June 2025. So, in seven months, we are already seeing that the plant is running at anywhere between 30% to 35% of its capacity."

Trade & Tariff: The Demand Reset

Dharmil A. Bodani: "So, if you are asking us a forward-looking question on the impact of this trade deal that we have had with the United States, it is extremely positive. I think it is in the right direction."

Segment Performance

SegmentTrendCommentary
Fragrance▲ StrongVery strong performance with sustainable benefits from softer raw material pricing and new wins with existing and new customers. R&D pipeline driven by the perfumery division acting as a beacon for the ingredients division.
Camphor▼ Under pressureProfitability under pressure, impacting the FMCG segment's normal outcome. The company is the world's only US FDA approved camphor manufacturer and also holds WHO and GMP certifications, playing a large role globally in the medical pain management space.
Bareilly▲ GrowthSales up 27% YoY despite being down sequentially, consistent with the seasonal curve.
Baroda▬ ResilientProduction up 15% YoY while the broader specialty ingredients market remains competitive and price sensitive.
FMCG▬ SteadyContinues to stay stronger, though camphor profitability pressure weighs on segment outcomes. Management declined to discuss FMCG sales strategy on the call.

Balance Sheet & Asset Cycle

Shyamal A. Bodani: "Importantly, when you step back and view performance the way global peers encourage investors to view it over a long arc rather than a quarter-to-quarter noise, the trend is reassuring."

Unanswered Questions & Pushback


Guidance & Commitments

CommitmentSpecificsTimeline
Sales growth8% to 10% growth in salesFY26 (current fiscal year)
Mahad profitability inflectionGetting into "some level of independence"Next two quarters
Order book execution"Pretty solid" order book; execute and continue same trajectoryH1 2026
US tariff situationDeclared resolved; "no rearview mirror"Effective immediately
Mahad utilization targetNo specific timeline given for 70–75% utilizationNot provided

Key Metrics

MetricQ3 FY26
Operating revenue₹252.03 cr, ~13% YoY growth
EBITDA₹13 cr, vs ₹23 cr in Q3 FY25
EBITDA margin5.26%
Net loss₹1.92 cr, vs net profit of ₹7.14 cr in Q3 FY25
PAT margin(-0.76%)
Operating revenue (9M FY26)₹748 cr, 11% YoY increase
EBITDA (9M FY26)₹49 cr, vs ₹73 cr in 9M FY25
EBITDA margin (9M FY26)6.49%, vs 10.85% in 9M FY25
Net loss (9M FY26)₹0.67 cr, vs net profit of ₹32.90 cr in 9M FY25
Cash profit (9M FY26)₹22.65 cr
Net debt-to-equity0.65x as of 31st Dec 2025
Production growth3% YoY
Sales volume growth10% YoY
Mahad plant utilization30% to 35% of capacity, production started June 2025
US sales exposure16% to 20% of total sales